We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The budget deal approved by lawmakers in the early hours on Friday raised caps on non-defense discretionary spending by $63 billion in fiscal 2018 and $68 billion in fiscal 2019, but FDA appropriations remain unclear. Read More
A bipartisan group of members of the Senate Health Committee introduced a bill to increase National Institutes of Health research into non-opioid pain treatments. Read More
A Washington, D.C. law firm petitioned the U.S. Attorney’s Office in Boston to reopen an investigation of Forest Laboratories, claiming the company misrepresented clinical trial results used as the basis for Lexapro’s approval for pediatric use. Read More
ViiV Healthcare filed a patent infringement complaint against Gilead’s new HIV drug Biktarvy on the same day the combination drug secured the FDA’s approval. Read More
The FDA issued 35 new draft and 22 revised product-specific guidances for generic drugs, including the pain treatment buprenorphine, the skin disorder treatment fluocinonide and the multiple myeloma drug ixazomib citrate. Read More